0%
Print report
Variant interpretation report

POLD1 c.242G>A, p.Arg81Gln

NM_002691.4:c.242G>A NP_002682.2:p.(Arg81Gln) Missense · exon 3 View identifiers
Classification
Uncertain significance

Variant description:

The POLD1 NM_002691.4:c.242G>A (NP_002682.2:p.(Arg81Gln)) missense variant has previously been reported in somatic cancers (COSMIC; COSV116510980, n = 1 time). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About POLD1

POLD1 encodes the catalytic subunit of DNA polymerase delta, an enzyme that carries both DNA synthesis and proofreading (3' to 5' exonuclease) activities and is essential for accurate DNA replication and repair. Germline mutations in its exonuclease domain cause polyposis and predispose people to colorectal, endometrial, and possibly brain cancers. In cancer, POLD1 defects impair replication fidelity, leading to the accumulation of many mutations (an ultra-mutated phenotype) that may make tumors more responsive to immunotherapy, though somatic POLD1 mutations are rare.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 0
Pathogenic criteria applied · 1
PM2Moderate
PM2 · moderate

Met at Moderate: gnomAD v4.1 total AF is 6.19575e-06, below the 0.0001 PM2 extremely-low-frequency cutoff.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: PM2 (moderate) is the only applied criterion, and one moderate criterion does not satisfy a generic ACMG/AMP pathogenic or benign combination rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
10 / 1,614,010 alleles

gnomAD v4.1: 10 / 1,614,010 alleles. Recorded AF 6.19575e-06. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 7.95526e-06; MAF= 0.00080%, 2/251406 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 6.15233e-05; MAF= 0.00615%, 1/16254 alleles, homozygotes = 0).

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 5.431240495329133e-05, 1/18412 alleles, homozygotes = 0).

No screenshot for this evidence
REVEL score
0.307 recorded score

Recorded REVEL score: 0.307. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied
ClinVar submissions
5 reported laboratory submissions

5 Uncertain significance. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. POLD1, a DNA polymerase, is infrequently altered by mutation in cancer.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
1 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV116510980, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 1 met · 7 not met · 16 not assessed · 4 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

No codon/residue/domain criterion is met at ACMG/AMP 2015 strength from the supplied evidence.

PS1, PM1, PP2, and BP1 remain not assessed because the required comparative or gene-wide evidence is incomplete; PM5 is not met because no pathogenic alternate missense change at Arg81 was identified.

No criterion in this group is met. PS4, PP4, and BP5 remain not_assessed because the required case-control, phenotype, or alternate-molecular-basis evidence is unavailable; PP5 and BP6 are not met because ClinVar has no exact-variant expert-panel classification and all five submissions are Uncertain significance.

The variant is missense, so PP3 and BP4 use the REVEL path only; the REVEL score of 0.307 is between the supplied BP4 cutoff of <=0.29 and PP3 cutoff of >=0.644, meeting neither criterion.

Population evidence supports PM2 at Moderate strength because the variant is present only at 6.19575e-06 in gnomAD v4.1, below the 0.0001 cutoff.

BA1 and BS1 are not met because the required gnomAD filtering frequency, grpmax FAF=2.47e-06, is far below their generic thresholds.

BS2 remains not assessed because allele counts do not document a healthy adult carrier or establish the relevant inheritance and penetrance context.

Met · 1

PM2 ModerateACMG_2015Met at Moderate: gnomAD v4.1 total AF is 6.19575e-06, below the 0.0001 PM2 extremely-low-frequency cutoff. Details ▾Hide ▴
Reasoning

PM2 is met at Moderate strength. The variant is present only at an extremely low frequency in the population datasets: gnomAD v4.1 total AF is 6.19575e-06 (10/1,614,010 alleles; zero homozygotes), and the required non-cancer subsets report 8.44252e-06 in gnomAD v2.1 non-cancer exomes (2/236,896 alleles) and 1.35228e-05 in gnomAD v3.1 non-cancer genomes (2/147,898 alleles; zero homozygotes). These values are all below the supplied generic PM2 cutoff of 0.0001. No governing VCEP specifies a different population source because no VCEP covers POLD1.

Rule
Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1 all-comers: AF=6.19575e-06 (10/1,614,010 alleles; homozygotes=0); exome AF=5.47249e-06 (8/1,461,858 alleles).
  • gnomAD v2.1 non-cancer exomes: AF=8.44252e-06 (2/236,896 alleles; homozygotes=0).
  • gnomAD v3.1 non-cancer genomes: AF=1.35228e-05 (2/147,898 alleles; homozygotes=0).
  • ACMG/AMP 2015 PM2 calibration supplied for this interpretation (PMID:25741868): extremely low frequency cutoff <=0.0001; all reported frequencies are below this cutoff.
Sources

Not met · 7 · evaluated, threshold not reached

PM5 ACMG_2015Not met: the p.Arg81Gln comparator search found zero same-residue candidates and zero pathogenic same-residue missense comparators. Details ▾Hide ▴
Reasoning

The variant is p.Arg81Gln. The case-specific comparator collection reports zero same-residue candidates and zero pathogenic or likely pathogenic same-residue candidates, so no different pathogenic missense change at Arg81 is available to satisfy PM5.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.
Evidence considered
  • pm5_candidates.json records total_candidates_seen=0, same_residue_candidates=0, expert_panel_plp_candidates=0, and non_expert_majority_plp_candidates=0 for POLD1 Arg81.
  • ClinVar variation 469259 is Uncertain significance and does not provide a pathogenic alternate missense change at Arg81.
Sources
pm5_candidatesclinvar ↗
PP3 ACMGNot met: missense REVEL score 0.307 is below the PP3 supporting threshold of >=0.644. Details ▾Hide ▴
Reasoning

PP3 is evaluated on the missense path because NM_002691.4:c.242G>A is a missense variant producing NP_002682.2:p.(Arg81Gln). Under the generic rule, the applicable predictor is REVEL only; SpliceAI and BayesDel are not used for this PP3 assessment. The REVEL score is 0.307, below the PP3 supporting cutoff of >=0.644, so PP3 is not met. ACMG/AMP 2015 defines PP3 as supporting computational evidence, and the supplied generic calibration permits PP3 only at supporting strength.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... PP3/BP4 take evidence from exactly ONE path, selected by the variant's own consequence type, never from both. ... Missense variant -> REVEL only. ... PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: missense, NM_002691.4:c.242G>A to NP_002682.2:p.(Arg81Gln), from the case normalization evidence.
  • Applicable computational path: missense -> REVEL only; the SpliceAI score and BayesDel score are not used for PP3/BP4 on this path.
  • Local REVEL predictor lookup: score 0.307 for NM_002691.4:c.242G>A.
  • Generic calibration supplied for this interpretation: REVEL PP3 supporting requires >=0.644 (Pejaver et al. 2022, PMID:36413997); 0.307 does not reach the cutoff.
  • Richards et al. 2015 computational guidance states that predictions are treated as a single evidence item rather than independent evidence from multiple similar tools.
Sources
PP5 ACMG_2015Not met: ClinVar has zero expert-panel submissions and all five exact-variant laboratory submissions classify POLD1 c.242G>A as uncertain significance. Details ▾Hide ▴
Reasoning

PP5 is not met. ClinVar variation 469259 contains five clinical-laboratory submissions, all classified as Uncertain significance, and the audit records zero expert-panel submissions. The papers linked from ClinVar do not provide an exact-variant pathogenic report. Thus, there is no exact-variant ClinVar expert-panel classification of Pathogenic or Likely pathogenic to support PP5.

Rule
PP5: Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 469259 exact-variant audit: five submissions, zero expert-panel submissions, and all submissions classified as Uncertain significance.
  • PMID:25394175 and PMID:33850299 full-text extractions do not mention POLD1 c.242G>A or p.Arg81Gln and therefore do not constitute an exact-variant pathogenic report.
  • Generic PP5 was restricted to an exact-variant ClinVar expert-panel Pathogenic or Likely pathogenic classification; that required classification is absent.
Sources
BA1 ACMG_2015Not met: gnomAD v4.1 grpmax FAF is 2.47e-06, far below the 0.05 BA1 stand-alone threshold. Details ▾Hide ▴
Reasoning

BA1 is not met. The governing generic frequency assessment uses the gnomAD v4.1 grpmax FAF rather than the highest population point estimate: grpmax FAF is 2.47e-06, far below the 0.05 stand-alone threshold. The highest observed population point estimate is only 1.667e-05 in Admixed American individuals (1/59,988 alleles), and the gnomAD v2.1 all-comers and non-cancer exome frequencies are also far below 5% (7.95526e-06 and 8.44252e-06, respectively). No high-frequency reduced-penetrance or pathogenic-consensus conflict is present that would require withholding BA1 beyond this frequency result.

Rule
Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1: joint grpmax FAF=2.47e-06; total AF=6.19575e-06 (10/1,614,010 alleles; homozygotes=0); highest observed population AF=1.667e-05 in Admixed American individuals (1/59,988 alleles).
  • gnomAD v2.1: total AF=7.95526e-06 (2/251,406 alleles; homozygotes=0). The non-cancer exome subset reports AF=8.44252e-06 (2/236,896 alleles; homozygotes=0).
  • ACMG/AMP 2015 BA1 calibration supplied for this interpretation (PMID:25741868): stand-alone threshold >=0.05; the applicable grpmax FAF is below that threshold by more than four orders of magnitude.
Sources
BS1 ACMG_2015Not met: gnomAD v4.1 grpmax FAF is 2.47e-06, below the generic BS1 threshold of 0.01. Details ▾Hide ▴
Reasoning

BS1 is not met on the available population data. Using the required filtering frequency, gnomAD v4.1 grpmax FAF is 2.47e-06, which is below the generic 0.01 threshold for an allele frequency greater than expected for the disorder. The v4.1 highest population point estimate, 1.667e-05 in Admixed American individuals, is not substituted for FAF. The observed frequencies are therefore not high enough to support BS1, irrespective of any unresolved disease prevalence or penetrance refinement.

Rule
Allele frequency is greater than expected for the disorder.
Evidence considered
  • gnomAD v4.1: required filtering value grpmax FAF=2.47e-06; total AF=6.19575e-06 (10/1,614,010 alleles); highest observed population AF=1.667e-05 in Admixed American individuals (1/59,988 alleles).
  • gnomAD v2.1: total AF=7.95526e-06 (2/251,406 alleles). The non-cancer exome subset reports AF=8.44252e-06 (2/236,896 alleles).
  • Generic SVI default supplied for this interpretation (Whiffin et al. 2017, PMID:28518168): BS1 threshold >=0.01. The filtering FAF is below this default, so no maximum-credible-frequency calculation is needed to reject the frequency-based BS1 path.
Sources
BP4 ACMGNot met: missense REVEL score 0.307 exceeds the BP4 supporting threshold of <=0.29. Details ▾Hide ▴
Reasoning

BP4 is evaluated on the missense path because NM_002691.4:c.242G>A is a missense variant producing NP_002682.2:p.(Arg81Gln). Under the generic rule, the applicable predictor is REVEL only; the low SpliceAI score cannot substitute for a gray-zone missense REVEL result, and BayesDel is not available for generic ACMG/AMP strength calibration. The REVEL score is 0.307, above the BP4 supporting cutoff of <=0.29, so BP4 is not met.

Rule
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc). ... PP3/BP4 take evidence from exactly ONE path, selected by the variant's own consequence type, never from both. ... Missense variant -> REVEL only. ... BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: missense, NM_002691.4:c.242G>A to NP_002682.2:p.(Arg81Gln), from the case normalization evidence.
  • Applicable computational path: missense -> REVEL only; the SpliceAI score is not evidence for BP4 on a missense path, and BayesDel has no established generic ACMG-strength calibration.
  • Local REVEL predictor lookup: score 0.307 for NM_002691.4:c.242G>A.
  • Generic calibration supplied for this interpretation: REVEL BP4 supporting requires <=0.29 (Pejaver et al. 2022, PMID:36413997); 0.307 is above the cutoff and is therefore not supportive of BP4.
  • Richards et al. 2015 computational guidance states that predictions are treated as a single evidence item rather than independent evidence from multiple similar tools.
Sources
BP6 ACMG_2015Not met: ClinVar has zero expert-panel submissions and no exact-variant Benign or Likely benign expert-panel classification. Details ▾Hide ▴
Reasoning

BP6 is not met. ClinVar variation 469259 has zero expert-panel submissions, and all five exact-variant clinical-laboratory submissions classify the variant as Uncertain significance. No exact-variant ClinVar expert-panel classification of Benign or Likely benign is present.

Rule
BP6: Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 469259 exact-variant audit: expert_panel_submissions = 0; all five submissions are Uncertain significance.
  • Generic BP6 was restricted to an exact-variant ClinVar expert-panel Benign or Likely benign classification; that required classification is absent.
Sources

Not assessed · 16 · no assessment recorded

PS1 ACMG_2015Not assessed: no previously established pathogenic Arg81Gln variant from a different nucleotide change is documented; ClinVar classifies this variant as uncertain significance. Details ▾Hide ▴
Reasoning

The variant is NP_002682.2:p.(Arg81Gln), but the supplied evidence does not establish a previously pathogenic variant producing the same Arg81Gln amino-acid change through a different nucleotide change. ClinVar variation 469259 is classified as Uncertain significance, not pathogenic, and no qualifying same-protein-change comparator is documented.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.
Evidence considered
  • ClinVar variation 469259 corresponds exactly to NM_002691.4:c.242G>A (NP_002682.2:p.(Arg81Gln)) and is classified as Uncertain significance with no expert-panel submission.
  • No source in the supplied case evidence establishes a pathogenic variant with the same amino-acid change caused by a different nucleotide change.
Still missing
  • A systematic search for previously established pathogenic variants encoding the same p.Arg81Gln change is not available.
Sources
PS2 ACMG_2015Not assessed: no documented proband phenotype, family-history status, or confirmed maternity and paternity is available for this variant. Details ▾Hide ▴
Reasoning

No case-specific evidence documents a patient with the disease, absence of family history, or confirmed maternity and paternity for NM_002691.4:c.242G>A; therefore the de novo criterion cannot be assessed.

Rule
PS2: De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • The case-specific materials provide no documented proband phenotype, family history, parental genotypes, maternity confirmation, or paternity confirmation for NM_002691.4:c.242G>A.
  • ClinVar variation 469259 lists five uncertain-significance submissions but does not provide de novo or parental-testing evidence for this variant.
Still missing
  • Documented disease phenotype for the proband
  • Family-history status
  • Variant testing results confirming maternity
  • Variant testing results confirming paternity
Sources
PS3 ACMG_2015Not assessed: no variant-specific validated in vitro or in vivo functional assay, controls, or reproducibility data were identified for POLD1 c.242G>A (p.Arg81Gln). Details ▾Hide ▴
Reasoning

The variant is NM_002691.4:c.242G>A (NP_002682.2:p.Arg81Gln). The available variant-specific literature and evidence records contain no validated in vitro or in vivo functional assay demonstrating a damaging effect, no assay controls or reproducibility data, and no clinical diagnostic laboratory functional validation. The reviewed publications either do not mention this variant or provide only general ACMG guidance or non-variant-specific POLD1 observations. Therefore, the evidence is insufficient to assess PS3 at its ACMG/AMP 2015 strong strength; computational predictions and the absence of an assay cannot establish PS3.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product. ... Functional studies that have been validated and shown to be reproducible and robust in a clinical diagnostic laboratory setting are considered the most well-established.
Evidence considered
  • The consolidated evidence records contain no variant-specific functional assay for NM_002691.4:c.242G>A (NP_002682.2:p.Arg81Gln).
  • PMID:25741868 was consulted for the ACMG/AMP 2015 functional-evidence definition; its extracted text provides general guidance and does not report a POLD1 c.242G>A assay.
  • PMID:29056344 reports cohort-level POLD1 variant analyses but does not mention c.242G>A or p.Arg81Gln and provides no functional result for this variant.
  • PMID:29950348 discusses POLD1 proofreading-domain variants but does not mention c.242G>A or p.Arg81Gln and provides no functional result for this variant.
Still missing
  • A variant-specific in vitro or in vivo functional study with appropriate positive and negative controls and reproducible results is needed.
  • Clinical diagnostic laboratory validation of the functional assay would strengthen assessment but is not present in the available evidence.
Sources
PS4 ACMG_2015Not assessed: no exact-variant case-control counts, odds ratio, or confidence interval were reported, so the PS4 requirement of OR/RR >5.0 cannot be evaluated. Details ▾Hide ▴
Reasoning

No PS4 conclusion can be reached. The literature packet lists PMID:25394175 and PMID:33850299 as PS4 leads, but their full-text extracts verify that neither mentions POLD1 c.242G>A or p.Arg81Gln. The other reviewed POLD1 papers likewise do not report this exact variant or a case-control comparison. No affected-versus-unaffected counts, case frequency, odds ratio, relative risk, or confidence interval are available, so the ACMG/AMP PS4 threshold cannot be evaluated. The governing numeric requirement is OR/RR >5.0 with a confidence interval that does not include 1.0; no value is available for an explicit inequality.

Rule
PS4: The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • PMID:25394175 full-text extraction: the paper does not mention POLD1, c.242G>A, or p.(R81Q).
  • PMID:33850299 full-text extraction: the paper does not mention POLD1 or c.242G>A / p.(R81Q).
  • PMID:29056344 full-text extraction: a cohort of 81,337 tumors included many POLD1 variants, but not this exact variant and no applicable affected-versus-control comparison was reported.
  • PMID:29950348 full-text extraction: the paper discusses POLD1 proofreading-domain variants but not c.242G>A / p.(R81Q), and supplies no applicable case-control data.
  • No exact-variant PS4 observation was identified in the already-read literature packet; gnomAD population frequency alone is not a case-control comparison for this variant.
Still missing
  • Exact-variant affected-case and unaffected/control counts or a reported odds ratio/relative risk with 95% confidence interval are needed.
Sources
PM1 ACMG_2015Not assessed: POLD1 R81 is outside the reported codons 245-571 proofreading domain and no hotspot was found, but a complete critical-domain assessment is unavailable. Details ▾Hide ▴
Reasoning

No statistically significant cancer hotspot was identified for POLD1 R81. The supplied gene-level literature defines the POLD1 exonuclease proofreading domain as codons 245-571, placing Arg81 outside that reported domain, but no complete gene-specific inventory of all critical functional domains or benign variation is available for generic PM1 assessment.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • Cancer Hotspots returned no statistically significant hotspot for POLD1 R81.
  • Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease, Results section ‘Mutations in DNA Polymerase Proof-reading Domains’: the paper defines the POLD1 exonuclease proofreading domain as codons 245-571; the evaluated residue is Arg81, outside that interval.
  • vcep_materials.json has no POLD1 domain_tables entry because no VCEP covers this gene.
Still missing
  • A complete, gene-specific list of POLD1 critical functional domains and evidence for absence of benign variation in any qualifying domain are unavailable.
Sources
PM3 ACMG_2015Not assessed: no affected-proband observation or parental/offspring testing establishes this variant in trans with a pathogenic variant. Details ▾Hide ▴
Reasoning

PM3 cannot be assessed because the available case evidence does not document an affected proband with this variant in trans with a pathogenic variant, nor does it provide parental or offspring testing establishing phase. The available ClinVar record is classified as uncertain significance and supplies no phase or affected-proband observations relevant to PM3.

Rule
PM3: For recessive disorders, detected in trans with a pathogenic variant ... Note: This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • ClinVar variation 469259 for NM_002691.4(POLD1):c.242G>A (p.Arg81Gln) contains five germline submissions, all classified as uncertain significance, and does not report an affected-proband observation, a second pathogenic variant, or phase information.
Still missing
  • Affected-proband case data with a confirmed pathogenic variant in the same individual.
  • Parental or offspring testing establishing trans phase.
Sources
PM6 ACMG_2015Not assessed: no assumed de novo occurrence or parental testing is documented for NM_002691.4:c.242G>A. Details ▾Hide ▴
Reasoning

No case-specific evidence documents an assumed de novo occurrence or any parental testing for NM_002691.4:c.242G>A; therefore PM6 cannot be assessed.

Rule
PM6: Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • The case-specific materials provide no report of de novo status, parental genotypes, or parental testing for NM_002691.4:c.242G>A.
  • ClinVar variation 469259 lists five uncertain-significance submissions without a parental-origin or de novo observation for this variant.
Still missing
  • Evidence that the variant was considered de novo
  • Parental genotype results or an explicit absence of parental testing
Sources
PP1 ACMG_2015Not assessed: zero affected relatives and zero informative meioses are documented for segregation of this variant. Details ▾Hide ▴
Reasoning

No affected relatives, variant-positive relatives, phenotype concordance, or informative meioses are documented for NM_002691.4:c.242G>A; therefore cosegregation cannot be assessed.

Rule
PP1: Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease. ... Note: May be used as stronger evidence with increasing segregation data.
Evidence considered
  • The case-specific materials contain no pedigree, affected-relative genotypes, cosegregation observations, phenotype concordance assessment, or meiosis count for NM_002691.4:c.242G>A.
  • No case-specific publication evidence reports segregation data for this variant.
Still missing
  • Pedigree identifying affected family members
  • Genotypes of affected relatives
  • Phenotype consistency among relatives
  • Number of informative meioses
PP2 ACMG_2015Not assessed: no gene-wide benign-missense rate and no evidence establishing missense variants as a common POLD1 disease mechanism are supplied. Details ▾Hide ▴
Reasoning

The supplied evidence does not provide a gene-wide benign missense rate or establish that missense variants are a common disease mechanism for POLD1 at the level required by PP2. Gene-level reports of selected POLD1 missense variants and proofreading-domain disease associations are insufficient to establish both PP2 components.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
  • The supplied case evidence contains variant-level population data but no gene-wide benign missense-rate analysis.
  • The available POLD1 literature describes selected proofreading-domain missense associations but does not establish the required gene-wide common missense mechanism.
Still missing
  • Gene-wide evidence quantifying benign missense variation is unavailable.
  • Gene-level evidence establishing missense variants as a common POLD1 disease mechanism is unavailable.
PP4 ACMG_2015Not assessed: the available evidence gives no patient phenotype or family-history details demonstrating a highly specific single-gene disease presentation. Details ▾Hide ▴
Reasoning

The available case evidence does not provide the patient's phenotype, family history, or a sufficiently specific clinical diagnosis. Therefore, it is not possible to determine whether the phenotype is highly specific for a disease with a single genetic etiology.

Rule
PP4: Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Evidence considered
  • The case evidence identifies the variant as POLD1 c.242G>A (p.Arg81Gln) and lists broad ClinVar condition labels, but does not document an individual phenotype or family history.
Still missing
  • A documented patient phenotype or family history and a disease-specificity assessment are needed.
BS2 Not assessed: gnomAD allele counts do not document a healthy adult carrier, age, phenotype exclusion, inheritance, or full penetrance. Details ▾Hide ▴
Reasoning

BS2 cannot be assessed from the available evidence. gnomAD reports heterozygous allele observations but does not document that a specific carrier was a healthy adult, establish the individual's age, or exclude the relevant POLD1 cancer-predisposition phenotype. The case evidence also does not establish the disorder's inheritance model, expected age of onset, or full penetrance. Therefore, the population allele counts cannot be treated as the required observation in a healthy adult individual.

Evidence considered
  • gnomAD v4.1 records 10 alternate alleles in 1,614,010 total alleles and zero homozygotes; it does not identify individual carrier ages or clinical phenotypes.
  • gnomAD v2.1 records 2 alternate alleles in 251,406 exome alleles and zero homozygotes; the non-cancer exome subset records 2/236,896 alleles and zero homozygotes, without healthy-adult phenotype documentation.
Still missing
  • A documented healthy adult individual carrying the variant, with age and relevant phenotype information.
  • Confirmed inheritance model, age-of-onset expectation, and penetrance for the applicable POLD1 disorder.
Sources
BS3 ACMG_2015Not assessed: no variant-specific validated assay demonstrated that POLD1 c.242G>A (p.Arg81Gln) has no damaging effect on protein function or splicing. Details ▾Hide ▴
Reasoning

The variant is NM_002691.4:c.242G>A (NP_002682.2:p.Arg81Gln). The available variant-specific literature and evidence records contain no validated in vitro or in vivo functional assay demonstrating no damaging effect on POLD1 protein function or splicing, no assay controls or reproducibility data, and no clinical diagnostic laboratory functional validation. The reviewed publications either do not mention this variant or provide only general ACMG guidance or non-variant-specific POLD1 observations. Therefore, the evidence is insufficient to assess BS3 at its ACMG/AMP 2015 strong strength; absence of a functional assay cannot establish BS3.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • The consolidated evidence records contain no variant-specific functional assay for NM_002691.4:c.242G>A (NP_002682.2:p.Arg81Gln) showing preserved protein function or normal splicing.
  • PMID:25741868 was consulted for the ACMG/AMP 2015 functional-evidence definition; its extracted text provides general guidance and does not report a POLD1 c.242G>A assay.
  • PMID:29056344 reports cohort-level POLD1 variant analyses but does not mention c.242G>A or p.Arg81Gln and provides no functional result for this variant.
  • PMID:29950348 discusses POLD1 proofreading-domain variants but does not mention c.242G>A or p.Arg81Gln and provides no functional result for this variant.
Still missing
  • A variant-specific in vitro or in vivo functional study showing no damaging effect on protein function or splicing is needed.
  • The study should include appropriate controls, reproducibility information, and assay validation sufficient for ACMG/AMP 2015 BS3 assessment.
Sources
BS4 ACMG_2015Not assessed: no affected relatives tested negative for NM_002691.4:c.242G>A are documented. Details ▾Hide ▴
Reasoning

No affected family members with documented absence of NM_002691.4:c.242G>A are identified, and no family structure or phenocopy assessment is available; therefore lack of segregation cannot be assessed.

Rule
BS4: Lack of segregation in affected members of a family.
Evidence considered
  • The case-specific materials provide no affected relatives, negative familial genotypes, pedigree, or non-segregation observation for NM_002691.4:c.242G>A.
  • No case-specific publication evidence reports lack of segregation for this variant.
Still missing
  • Affected family members eligible for testing
  • Negative variant-test results in affected relatives
  • Pedigree and phenotype documentation
  • Assessment of phenocopies or more than one pathogenic variant in the family
BP1 ACMG_2015Not assessed: available evidence documents POLD1 missense disease associations but does not quantify whether disease is caused primarily by truncating variants. Details ▾Hide ▴
Reasoning

The supplied evidence does not establish that POLD1 disease is caused primarily by truncating variants. Available gene-level evidence instead documents disease-associated missense variation in the exonuclease proofreading domain, but it does not quantify the relative contribution of truncating versus missense variants across the gene.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Evidence considered
  • Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease, Results section ‘Mutations in DNA Polymerase Proof-reading Domains’: germline POLD1 mutations are reported in the exonuclease proofreading domain (codons 245-571), demonstrating disease-associated missense context but not a primarily truncating disease spectrum.
Still missing
  • A comprehensive POLD1 disease-variant spectrum comparing truncating and missense mechanisms is unavailable.
Sources
BP2 ACMG_2015Not assessed: no parental, offspring, or haplotype data establish this variant in trans or cis with a pathogenic variant. Details ▾Hide ▴
Reasoning

BP2 cannot be assessed because the available case evidence does not document this variant in trans with a pathogenic variant in a fully penetrant dominant disorder, or in cis with a pathogenic variant in any inheritance pattern. No parental, offspring, haplotype, or other phase data are provided. The available ClinVar record is classified as uncertain significance and supplies no phase observations relevant to BP2.

Rule
BP2: Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • ClinVar variation 469259 for NM_002691.4(POLD1):c.242G>A (p.Arg81Gln) contains five germline submissions, all classified as uncertain significance, and does not report cis/trans phase or a pathogenic variant in the same individual.
Still missing
  • Phase-resolved observation of this variant in trans with a pathogenic variant for a fully penetrant dominant disorder, or in cis with a pathogenic variant.
Sources
BP5 ACMG_2015Not assessed: no exact-variant case evidence shows an alternate molecular basis for the patient's disease. Details ▾Hide ▴
Reasoning

No case-level evidence documents that this variant was found in a patient with an alternate molecular basis for the disease. The available ClinVar record contains no such case description, and the reviewed publications do not report an exact-variant case with an alternative molecular diagnosis.

Rule
BP5: Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • ClinVar variation 469259 provides only Uncertain significance submissions and no case-level alternate molecular diagnosis.
  • PMID:25394175 and PMID:33850299 full-text extractions do not mention the exact POLD1 variant.
Still missing
  • A case report or clinical record documenting the variant together with a confirmed alternate molecular basis for disease is needed.
Sources
Not applicable · 4· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_002691.4:c.242G>A in POLD1 is a missense substitution predicted to produce NP_002682.2:p.(Arg81Gln). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for POLD1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_002691.4:c.242G>A in POLD1 is a missense substitution predicted to produce NP_002682.2:p.(Arg81Gln). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for POLD1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_002691.4:c.242G>A in POLD1 is a missense substitution predicted to produce NP_002682.2:p.(Arg81Gln). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for POLD1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_002691.4:c.242G>A in POLD1 is a missense substitution predicted to produce NP_002682.2:p.(Arg81Gln). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for POLD1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
POLD1
Transcript
NM_002691.4
Coding (HGVS c.)
NM_002691.4:c.242G>A
Protein (HGVS p.)
NP_002682.2:p.(Arg81Gln)
GRCh38
chr19:50399410 G>A
GRCh37
chr19:50902667 G>A
Location and type
Exon 3 · missense
ClinVar
469259
COSMIC
COSV116510980

Gene diagram

Every interpreted variant in POLD1, mapped onto the exon structure of NM_002691.4. Select a row to find it on the plot.

POLD1NM_002691.4
Fetching transcript structure from UCSC…
gnomAD v4.1 10 / 1,614,010 alleles AF 6.2e-06 · 0 homozygotes · FAF 2.47e-06
gnomAD v2.1 2 / 251,406 alleles AF 7.96e-06 · 0 homozygotes
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 6.2e-06 · 10 / 1,614,010 alleles · 0 hom · FAF 2.5e-06
Admixed American1 / 59,988 1.7e-05
African/African American1 / 74,906 1.3e-05
South Asian1 / 91,086 1.1e-05
European (non-Finnish)7 / 1,180,018 5.9e-06
0 alternate alleles recorded in 6 other groups: Remaining individuals, European (Finnish), Amish, East Asian, Middle Eastern, Ashkenazi Jewish.

gnomAD v2.1

AF 8e-06 · 2 / 251,406 alleles · 0 hom
African/African American1 / 16,254 6.2e-05
Admixed American1 / 34,590 2.9e-05
0 alternate alleles recorded in 6 other groups: Ashkenazi Jewish, East Asian, European (Finnish), European (non-Finnish), Remaining individuals, South Asian.

gnomAD-Canada

AF not recorded · ? / ? alleles

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 6.19575e-06; MAF= 0.00062%, 10/1614010 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 1.667e-05; MAF= 0.00167%, 1/59988 alleles, homozygotes = 0); grpmax FAF= 2.47e-06.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 7.95526e-06; MAF= 0.00080%, 2/251406 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 6.15233e-05; MAF= 0.00615%, 1/16254 alleles, homozygotes = 0).

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 5.431240495329133e-05, 1/18412 alleles, homozygotes = 0).

Open the gnomAD-Canada detail page →

SpliceAI and Pangolin

SpliceAI acceptor lossat -34 bp
0.024
SpliceAI acceptor gainat -154 bp
0.040
SpliceAI donor lossat +70 bp
0.010
SpliceAI donor gainat +93 bp
0.000
Pangolin splice lossmagnitude shown
-0.021
Pangolin splice gain
0.019

Other predictors

REVEL
0.307
BayesDel
-0.224

How the predictions were used

PP3 ACMGNot met: missense REVEL score 0.307 is below the PP3 supporting threshold of >=0.644. Details ▾Hide ▴
Reasoning

PP3 is evaluated on the missense path because NM_002691.4:c.242G>A is a missense variant producing NP_002682.2:p.(Arg81Gln). Under the generic rule, the applicable predictor is REVEL only; SpliceAI and BayesDel are not used for this PP3 assessment. The REVEL score is 0.307, below the PP3 supporting cutoff of >=0.644, so PP3 is not met. ACMG/AMP 2015 defines PP3 as supporting computational evidence, and the supplied generic calibration permits PP3 only at supporting strength.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... PP3/BP4 take evidence from exactly ONE path, selected by the variant's own consequence type, never from both. ... Missense variant -> REVEL only. ... PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: missense, NM_002691.4:c.242G>A to NP_002682.2:p.(Arg81Gln), from the case normalization evidence.
  • Applicable computational path: missense -> REVEL only; the SpliceAI score and BayesDel score are not used for PP3/BP4 on this path.
  • Local REVEL predictor lookup: score 0.307 for NM_002691.4:c.242G>A.
  • Generic calibration supplied for this interpretation: REVEL PP3 supporting requires >=0.644 (Pejaver et al. 2022, PMID:36413997); 0.307 does not reach the cutoff.
  • Richards et al. 2015 computational guidance states that predictions are treated as a single evidence item rather than independent evidence from multiple similar tools.
Sources
BP4 ACMGNot met: missense REVEL score 0.307 exceeds the BP4 supporting threshold of <=0.29. Details ▾Hide ▴
Reasoning

BP4 is evaluated on the missense path because NM_002691.4:c.242G>A is a missense variant producing NP_002682.2:p.(Arg81Gln). Under the generic rule, the applicable predictor is REVEL only; the low SpliceAI score cannot substitute for a gray-zone missense REVEL result, and BayesDel is not available for generic ACMG/AMP strength calibration. The REVEL score is 0.307, above the BP4 supporting cutoff of <=0.29, so BP4 is not met.

Rule
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc). ... PP3/BP4 take evidence from exactly ONE path, selected by the variant's own consequence type, never from both. ... Missense variant -> REVEL only. ... BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: missense, NM_002691.4:c.242G>A to NP_002682.2:p.(Arg81Gln), from the case normalization evidence.
  • Applicable computational path: missense -> REVEL only; the SpliceAI score is not evidence for BP4 on a missense path, and BayesDel has no established generic ACMG-strength calibration.
  • Local REVEL predictor lookup: score 0.307 for NM_002691.4:c.242G>A.
  • Generic calibration supplied for this interpretation: REVEL BP4 supporting requires <=0.29 (Pejaver et al. 2022, PMID:36413997); 0.307 is above the cutoff and is therefore not supportive of BP4.
  • Richards et al. 2015 computational guidance states that predictions are treated as a single evidence item rather than independent evidence from multiple similar tools.
Sources
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_002691.4:c.242G>A in POLD1 is a missense substitution predicted to produce NP_002682.2:p.(Arg81Gln). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for POLD1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.04). REVEL score = 0.307. BayesDel score = -0.223518.

3 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    Richards S et al. · 2015
    This paper provides the ACMG/AMP 2015 framework for functional evidence but does not mention POLD1 c.242G>A or p.Arg81Gln and reports no assay result for this variant.
    Does not name this variant
    PMID 25741868 ↗
    Quoted passage
    While many of the different software programs use different algorithms for their predictions, they have similarities in their underlying basis; therefore, the combination of predictions from different in-silico tools are considered as a single piece of evidence in sequence interpretation as opposed to independent pieces of evidence.

    Computational (In Silico) Predictive Programs

  • A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.
    Hampel H et al. · 2015
    This paper is a general cancer-predisposition referral guideline and does not mention POLD1 c.242G>A or p.Arg81Gln; it provides no exact-variant case-control, phenotype, or pathogenicity evidence.
    Does not name this variant
    PMID 25394175 ↗
  • Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.
    Singhal D et al. · 2021
    This paper analyzes pathogenic germline variants in 202 patients with hematological malignancies and another cancer, but does not mention POLD1 or c.242G>A / p.Arg81Gln; it therefore supplies no exact-variant PS4, PP5, or BP5 evidence.
    Does not name this variant
    PMID 33850299 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 6.19575e-06; MAF= 0.00062%, 10/1614010 alleles, homozygotes = 0) and has highest observed frequency in the Admixed American population (AF= 1.667e-05; MAF= 0.00167%, 1/59988 alleles, homozygotes = 0); grpmax FAF= 2.47e-06.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 7.95526e-06; MAF= 0.00080%, 2/251406 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 6.15233e-05; MAF= 0.00615%, 1/16254 alleles, homozygotes = 0).

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 5.431240495329133e-05, 1/18412 alleles, homozygotes = 0).

ClinVar

This variant has been reported in ClinVar as Uncertain significance (5 clinical laboratories). (ClinVarID = 469259)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.04). REVEL score = 0.307. BayesDel score = -0.223518.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. POLD1, a DNA polymerase, is infrequently altered by mutation in cancer.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV116510980, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.